MedPharm Ltd, a world-leading contract developer of topical and transdermal pharmaceutical products, has taken the first steps to expand its manufacturing capacity in the US to complement an existing manufacturing facility in the UK. MedPharm has obtained a facility in Durham, NC which will house liquid and semi-solid manufacturing and packaging capabilities with an initial capacity of up to 250kg. Located within a few miles of MedPharm’s current Center of Excellence in RTP, this facility is expected to complete initial qualification by the start of Q4 2020.
The new site gives MedPharm’s US based clients the opportunity to manufacture clinical batches and early stage development scale domestically. The facility is expected to further expand the number and type of manufacturing lines in the future based on market demand.
“MedPharm’s investment in this facility is a clear demonstration of our commitment to a global vision to expand services downstream towards manufacturing’ stated Eugene Ciolfi, MedPharm’s President and CEO. “MedPharm can now offer both clinical manufacture and formulation development for topical products in North America to complement similar services established for 20 years in the UK.”
About MedPharm
MedPharm is the world’s leading contract provider of topical and transdermal product design and formulation development services. MedPharm is experts at reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through their unique, cost-effective and industry-leading performance testing models. Well established as the global leaders in dermatology, nail, mucosal membrane, and transdermal product development, MedPharm can also offer innovative solutions for ophthalmic and airway preparations recognised for their scientific rigour by regulators and investors. MedPharm has fully established Centers of Excellence in the USA and the UK.
